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Sir,
In the changing scenario of today’s world, many women are conceiving 
at a later age, and there is an increase in pregnant women requiring 
drug treatment for chronic conditions such as diabetes, hypertension, 
epilepsy, or asthma. It is not possible to withhold drug therapy in such 
cases as these conditions may endanger the lives of both mother and 
baby. It thus becomes essential that both health-care provider and the 
woman, have accessible, cognizable and unambiguous pregnancy and 
lactation information to assess risk versus benefit while opting for a 
drug treatment [1,2]. However, there is a greater appreciation for risks 
involved with drug use in pregnancy and physicians mostly adhere to 
the prescription guidelines [3,4].
The existing letter risk categorization of drugs (A, B, C, D, and X) 
was often confusing to both physicians and the patients and led to a 
lot of misinformation. The risk versus benefit assessment was also 
often difficult. To alleviate these concerns, the U.S. Food and Drug 
Administration decided to implement the pregnancy and lactation 
labeling final rule (PLLR) which came into effect on June 30, 2015. This 
rule was designed to improve risk versus benefit assessment of drugs 
used in pregnant and nursing mothers. It is intended to provide clear 
and detailed information for both patients and health-care providers in 
narrative sections under three main categories - pregnancy, lactation, 
and females and males of reproductive potential [5,6].
The pregnancy category will deal with information pertaining to the 
use of drugs in pregnant women, like dosing and probable risks to the 
developing fetus, and also information about whether there is a registry 
that collects and maintains data on the effects of the drug or biological 
product on pregnant women. The lactation category will consist of 
information about using medications during breastfeeding, such as 
the amount of drug secreted in breast milk and possible effects on the 
breastfed child. The females and males of the reproductive potential 
category will provide data about pregnancy testing, contraception, and 
about infertility as it relates to the drug. Although this information has 
been included in labeling, there was no particular categorization for it 
until now [7].
While the implementation of this new rule will provide elaborate and 
accurate information to health-care providers when making decisions 
about drug therapy in patients who are pregnant and breastfeeding, it 
also entrusts larger responsibility on the practitioners to ensure the 
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safety of their patients. The physicians have to make more of an effort 
to be well-educated and aware about risks and benefits associated with 
the prescribed drug [5]. The misinterpretation of risk of drugs in the old 
pregnancy letter category system that has overwhelmed practitioners 
and patients will definitely be minimized by PLLR; however, over-the-
counter medications will still be subject to the old system. A time period 
of 3-5 years may be necessary for implementation and smooth operation 
of the rule, but the labeling of drugs is a step in the right direction [8].
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